A groundbreaking discovery in antibody research could offer hope to those battling polycystic kidney disease (PKD), a challenging inherited disorder. The race to find a cure for PKD has gained momentum with this new development.
PKD is characterized by the gradual formation of fluid-filled cysts within the kidneys, which, over time, impair the organs' functionality and can lead to the need for dialysis. Currently, there is no cure available.
Researchers at UC Santa Barbara have embarked on a novel therapeutic journey, utilizing carefully crafted monoclonal antibodies to disrupt the relentless growth of these cysts. Thomas Weimbs, a biologist and senior author of the study published in Cell Reports Medicine, emphasizes the urgency: "The cysts just keep growing endlessly, and we're determined to put a stop to it."
But here's where it gets controversial: the team is exploring a unique approach using monoclonal antibodies, which are lab-made proteins commonly employed in immunotherapy. These antibodies have the potential to be more selective than traditional small-molecule drugs, but they face a significant challenge - the most commonly produced form, immunoglobulin G (IgG), is too large to penetrate the cysts.
Weimbs explains, "IgG antibodies are highly successful in cancer therapy, but they cannot cross the cell layers and enter the cysts. This is crucial because the interior of each cyst is where the disease-driving activity occurs."
The team's innovative solution is to use dimeric immunoglobulin A (dIgA), a monoclonal antibody that can cross epithelial membranes. In nature, dIgA is part of the immune system, released into bodily fluids like tears and saliva to provide an early defense against pathogens. Weimbs and his colleagues proposed that dIgA, by binding to specific receptors on epithelial cells, could move into kidney cysts, targeting the receptors involved in the growth cycle.
The new study builds on this concept, demonstrating that dIgA can effectively target the cell mesenchymal-epithelial transition (cMET) receptor, a key driver of cyst development. The research team modified the antibody, converting it from IgG to dIgA, and then tested it in mouse models. The results were promising - the antibody successfully entered the cysts and remained there, reducing the activity of the cMET receptor and the signals that encourage cell growth.
Furthermore, the treatment triggered apoptosis (cell death) in cyst epithelial cells without harming healthy renal tissue. Weimbs and his team are optimistic about the potential of this approach, but they acknowledge that the work is still in its preclinical stages. They face challenges in finding partners interested in PKD therapies, accessing the technology to generate more antibody variants, and identifying additional biological targets.
Weimbs highlights the potential for further exploration: "There are numerous growth factors active in cyst fluids, as shown in the literature. Comparing the blocking of different growth factors and receptors could lead to more effective treatments and potentially even reverse the disease. We can explore combining different antibodies against various receptors simultaneously."
This research, led by Margaret F. Schimmel, also involved Bryan C. Bourgeois, Alison K. Spindt, Sage A. Patel, Tiffany Chin, Gavin E. Cornick, and Yuqi Lu at UCSB. It represents a significant step forward in the fight against PKD, offering a glimmer of hope for those affected by this debilitating disease.
